RU2021114228A - Способ лечения синдрома прадера-вилли - Google Patents

Способ лечения синдрома прадера-вилли Download PDF

Info

Publication number
RU2021114228A
RU2021114228A RU2021114228A RU2021114228A RU2021114228A RU 2021114228 A RU2021114228 A RU 2021114228A RU 2021114228 A RU2021114228 A RU 2021114228A RU 2021114228 A RU2021114228 A RU 2021114228A RU 2021114228 A RU2021114228 A RU 2021114228A
Authority
RU
Russia
Prior art keywords
inhibitor
phosphodiesterase
paragraphs
receptor agonist
subject
Prior art date
Application number
RU2021114228A
Other languages
English (en)
Inventor
Лиза Коул БЕРНЕТТ
Дитер ЭГЛИ
Рудольф Л. ЛЕЙБЕЛ
Сара КОТТЕР
Original Assignee
Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк
Лево Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк, Лево Терапьютикс, Инк. filed Critical Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк
Publication of RU2021114228A publication Critical patent/RU2021114228A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (14)

1. Применение ингибитора фосфодиэстеразы-4 для лечения заболевания, связанного со сниженными уровнями и/или активностью PC1 (прогормон-конвертазы 1) у субъекта.
2. Применение ингибитора фосфодиэстеразы-4 для лечения субъекта с ожирением, моногенным ожирением или синдромным ожирением; субъекта с инактивирующей мутацией в генах POMC, PCSK1 или MC4R; субъекта с синдромом Шааф-Янга; или субъекта с расстройством аутического спектра.
3. Применение по п. 1, в котором экспрессия прогормон-конвертазы повышается ингибитором фосфодиэстеразы-4.
4. Применение по любому из пп. 1-3, в котором введение ингибитора фосфодиэстеразы-4 приводит к одному или более из следующих улучшений у субъекта: уменьшению или улучшению гиперфагии; повышению уровней PCSK1; повышению уровня и/или активности PC1; снижению соотношения циркулирующего проинсулина к инсулину; снижению соотношения циркулирующего прогрелина к грелину; снижению соотношения циркулирующего POMC (проопиомеланокортин) к АКТГ (адренокортикотропный гормон); облегчению гипотиреоза, снижению соотношения циркулирующего проокситоцина к окситоцину; снижению соотношения циркулирующего про-НФГМ к НФГМ (нейротрофический фактор головного мозга); и снижению уровней незрелых гормонов; причем симптом, уровни или соотношения употребляются применительно к симптому, уровням или соотношениям заболевания пациента.
5. Применение по любому из пп. 1-3, в котором у субъекта улучшается один или более из следующих симптомов: гиперфагия, пониженная интенсивность метаболизма, ожирение, гипогонадизм, гипоадренализм, сниженная выработка гормона роста, пониженный мышечный тонус, нарушения сна, нарушения со стороны желудочно-кишечного тракта, пониженная выносливость, пониженная способность к концентрации, ухудшение когнитивной деятельности, поведенческие нарушения, тревожное расстройство, задержка роста, пониженная способность превращения незрелых гормонов в зрелые и активные формы и диабет.
6. Применение по любому из пп. 1-5, в котором ингибитор фосфодиэстеразы-4 вводят перорально, внутривенно, подкожно, интратекально, местно, интраназально или в легкие.
7. Применение по любому из пп. 1-6, в котором ингибитор фосфодиэстеразы-4 выбран из группы, состоящей из теофиллина, рофлумиласта, апремиласта, ибдуласта, GSK356278, MK0952, 3-изобутил-1-метилксантина (ИБМК) и их комбинаций.
8. Применение по любому из пп. 1-6, в котором ингибитор фосфодиэстеразы-4 является селективным ингибитором фосфодиэстеразы-4.
9. Применение по п. 8, в котором селективный ингибитор фосфодиэстеразы-4 представляет собой AN2728, апремиласт, циломиласт, кризаборол, BPN14770, PF-02545920, PF-00489791, PF-04447943, PF-05180999, PF-2545920, пикламиласт, рофлумиласт, ролипрам, E6005, GSK356278 или MK0952.
10. Применение по любому из пп. 1-6, в котором ингибитор фосфодиэстеразы-4 является неселективным ингибитором фосфодиэстеразы-4.
11. Применение по п. 10, в котором неселективный ингибитор фосфодиэстеразы-4 представляет собой метилированный ксантин или его производное, кофеин, аминофиллин, 3-изобутил-1-метилксантин (ИБМК), параксантин, пентоксифиллин, теобромин или теофиллин.
12. Применение по любому из пп. 1-11, в котором субъект имеет ожирение.
13. Применение по любому из пп. 1-12, в котором субъект представляет собой пациента с синдромом Шааф-Янга или расстройством аутического спектра.
14. Применение по любому из пп. 1-13, в котором применение дополнительно включает введение дополнительного терапевтического агента, представляющего собой инсулин, агонист рецептора инсулина, грелин, агонист рецептора грелина, РГГР (рилизинг-гормон гормона роста), агонист рецептора РГГР, альфа-МСГ (эндогенный лиганд рецептора меланокортина 4), агонист рецептора альфа-МСГ, окситоцин, агонист рецептора окситоцина, орексин, агонист рецептора орексина, НФГМ, агонист рецептора НФГМ, вазопрессин, агонист рецептора вазопрессина, нейропептид Y, агонист рецептора нейропептида Y, АПБ (агути-подобный белок), агонист рецептора АПБ, гонадотропин, агонист рецептора гонадотропина или их комбинации.
RU2021114228A 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли RU2021114228A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662345133P 2016-06-03 2016-06-03
UA62/345,133 2016-06-03
US201662375662P 2016-08-16 2016-08-16
US62/375,662 2016-08-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018147040A Division RU2748294C2 (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли

Publications (1)

Publication Number Publication Date
RU2021114228A true RU2021114228A (ru) 2021-06-01

Family

ID=60479034

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018147040A RU2748294C2 (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли
RU2021114228A RU2021114228A (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2018147040A RU2748294C2 (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли

Country Status (14)

Country Link
US (2) US10842775B2 (ru)
EP (2) EP3478281B1 (ru)
JP (2) JP7044768B2 (ru)
KR (1) KR102478186B1 (ru)
CN (1) CN109562092B (ru)
AU (1) AU2017275652B2 (ru)
BR (1) BR112018075039A2 (ru)
CA (1) CA3026083C (ru)
ES (1) ES2847126T3 (ru)
IL (2) IL263412B (ru)
MX (2) MX2018014942A (ru)
RU (2) RU2748294C2 (ru)
WO (1) WO2017210540A1 (ru)
ZA (1) ZA201808607B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026083C (en) * 2016-06-03 2024-04-02 The Trustees Of Columbia University In The City Of New York Methods of treating prader-willi syndrome
WO2018183923A1 (en) * 2017-03-31 2018-10-04 Epizyme, Inc. Methods of using ehmt2 inhibitors
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
US10736894B2 (en) 2018-02-15 2020-08-11 Ovid Therapeutics Inc. Methods of treating developmental syndromes with PDE10A inhibitors
TW202031283A (zh) 2018-09-20 2020-09-01 馬克 Ｃ 曼寧 穩定卡貝縮宮素鼻內製劑
CN111264851A (zh) * 2020-03-03 2020-06-12 河南省儿童医院郑州儿童医院 Pws综合征靶向替代保健食品及其制备方法
WO2022235818A2 (en) * 2021-05-04 2022-11-10 Virginia Tech Intellectual Properties, Inc. Conjugated linoleic acid supplementation for disease treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3270301A (en) * 1999-11-13 2001-05-30 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2001253886A1 (en) * 2000-04-12 2001-10-30 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
WO2004096222A1 (en) * 2003-04-30 2004-11-11 Switch Biotech Ag Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
US20080250516A1 (en) 2004-03-06 2008-10-09 Irm Llc Prohormone Convertase 1 Mutation Associated with Obesity
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
CN101361754B (zh) 2007-08-09 2013-04-17 李凌松 稀土元素盐或其药物组合物在制备治疗或预防糖尿病和肥胖症药物中的用途
WO2010062681A2 (en) * 2008-10-30 2010-06-03 University Of South Florida Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
JPWO2011083718A1 (ja) 2010-01-05 2013-05-13 学校法人慶應義塾 肺再生促進剤
WO2012154814A1 (en) 2011-05-09 2012-11-15 Eip Pharma, Llc Compositions and methods for treating alzheimer's disease
WO2014197753A1 (en) * 2013-06-08 2014-12-11 Sedogen, Llc Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia
ES2733552T3 (es) * 2014-01-24 2019-11-29 Celgene Corp Procedimientos para el tratamiento de la obesidad mediante apremilast
CA2966907C (en) * 2014-11-14 2021-09-07 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA3026083C (en) * 2016-06-03 2024-04-02 The Trustees Of Columbia University In The City Of New York Methods of treating prader-willi syndrome

Also Published As

Publication number Publication date
US20210113521A1 (en) 2021-04-22
AU2017275652A1 (en) 2018-12-20
ES2847126T3 (es) 2021-07-30
CA3026083C (en) 2024-04-02
EP3478281B1 (en) 2020-12-02
MX2018014942A (es) 2019-04-24
EP3831376A1 (en) 2021-06-09
RU2748294C2 (ru) 2021-05-21
MX2020009939A (es) 2021-01-15
US11957656B2 (en) 2024-04-16
CA3026083A1 (en) 2017-12-07
KR102478186B1 (ko) 2022-12-15
US10842775B2 (en) 2020-11-24
JP2019522045A (ja) 2019-08-08
CN109562092B (zh) 2023-08-22
IL263412A (en) 2018-12-31
IL263412B (en) 2022-08-01
JP2022058673A (ja) 2022-04-12
JP7044768B2 (ja) 2022-03-30
KR20190031209A (ko) 2019-03-25
RU2018147040A3 (ru) 2020-09-30
BR112018075039A2 (pt) 2019-05-14
WO2017210540A1 (en) 2017-12-07
US20190298686A1 (en) 2019-10-03
JP7329634B2 (ja) 2023-08-18
EP3478281A4 (en) 2020-02-26
IL294407A (en) 2022-08-01
RU2018147040A (ru) 2020-07-09
EP3478281A1 (en) 2019-05-08
CN109562092A (zh) 2019-04-02
AU2017275652B2 (en) 2023-02-16
ZA201808607B (en) 2019-08-28

Similar Documents

Publication Publication Date Title
RU2021114228A (ru) Способ лечения синдрома прадера-вилли
Fukudo Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation
Korpi et al. Mechanisms of action and persistent neuroplasticity by drugs of abuse
Lu et al. Alcohol, stress hormones, and the prefrontal cortex: a proposed pathway to the dark side of addiction
Tsigos et al. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress
Bruijnzeel Neuropeptide systems and new treatments for nicotine addiction
Park et al. Changes in basal hypothalamo-pituitary-adrenal activity during exercise training are centrally mediated
WO2006052468A3 (en) Adrenocorticotropic hormone analogs and related methods
da Silva et al. Neuropeptides in sepsis: from brain pathology to systemic inflammation
AU2016289271A1 (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
Muzar et al. The neurobiology of the Prader-Willi phenotype of fragile X syndrome
NZ597222A (en) Substituted 8-[6-Amino-3-Pyridyl]Xanthines
Gelot et al. Opioid dosing in renal and hepatic impairment
US20180244623A1 (en) N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto
Fukudo et al. Can modulating corticotropin releasing hormone receptors alter visceral sensitivity?
Hayes et al. Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3
Pace et al. Hindbrain adrenergic/noradrenergic control of integrated endocrine and autonomic stress responses
Qi et al. A critical role for the melanocortin 4 receptor in stress‐induced relapse to nicotine seeking in rats
Girault et al. Central administration of an orexin receptor 1 antagonist prevents the stimulatory effect of Olanzapine on endogenous glucose production
Chen et al. NBI 30775 (R121919), an orally active antagonist of the corticotropin‐releasing factor (CRF) type‐1 receptor for the treatment of anxiety and depression
Margatho et al. Serotonergic mechanisms of the lateral parabrachial nucleus in renal and hormonal responses to isotonic blood volume expansion
de Toledo Ramos et al. Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects
CN103750609A (zh) 一种带凳子的拐杖
Korostiy et al. Neurobiological basis of mutual influence of stress burden and alcohol addiction: Review of data
Torpy et al. Stress and critical illness: the integrated immune/hypothalamic-pituitary-adrenal axis response